The high failure rate of drugs in human trials after passing animal tests stems from a fundamental biological reality: a "mouse is not a small human." This "structural mismatch" is especially severe for modern, human-specific therapies like CAR-T and RNA, rendering animal models poor proxies.

While AI excels at screening vast compound libraries for potential drug candidates, it cannot overcome the ultimate bottleneck: the messy, complex, and poorly documented reality of human biology. The need for physical clinical trials remains the fundamental constraint on medical progress.

The high failure rate in drug development is analogous to trying to repair a car with no mechanical knowledge—it's just "banging on different parts." This highlights the industry's need to shift from observing correlations to understanding the fundamental biological mechanisms of disease.

Only 5% of investigational cancer drugs reach the market due to the gap between lab models and human biology. Dr. Saav Solanki highlights organoids, which use real patient tissue, as a key translational model to improve the predictive accuracy of preclinical research and increase the low success rate.

Despite AI's power, 90% of drugs fail in clinical trials. John Jumper argues the bottleneck isn't finding molecules that target proteins, but our fundamental lack of understanding of disease causality, like with Alzheimer's, which is a biology problem, not a technology one.

The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.

With over 5,000 oncology drugs in development and a 9-out-of-10 failure rate, the current model of running large, sequential clinical trials is not viable. New diagnostic platforms are essential to select drugs and patient populations more intelligently and much earlier in the process.

While AI is on the verge of cracking preclinical challenges, the biggest problem is the high drug failure rate in human trials. The next wave of innovation will use AI to design molecules for properties that predict human efficacy, addressing the fundamental reason drugs fail late-stage.

The bottleneck for AI in drug development isn't the sophistication of the models but the absence of large-scale, high-quality biological data sets. Without comprehensive data on how drugs interact within complex human systems, even the best AI models cannot make accurate predictions.